YWHAQ Protein

Migration, Crosslink

📖

YWHAQ Protein

active

wiki page Created: 2026-04-02T07:19:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-ywhaq-protein

📖 Wiki Page

protein1389 wordssynced 2026-04-02

YWHAQ Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">YWHAQ Protein</th>
</tr>
<tr>
<td class="label">Client</td>
<td>Binding Site</td>
</tr>
<tr>
<td class="label">BAD</td>
<td>Ser112, Ser136</td>
</tr>
<tr>
<td class="label">BAX</td>
<td>Ser184</td>
</tr>
<tr>
<td class="label">RAF1</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">TRADD</td>
<td>Various</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Peptide inhibitors</td>
<td>R18 derivatives</td>
</tr>
<tr>
<td class="label">Stabilizers</td>
<td>Fusicoccin</td>
</tr>
<tr>
<td class="label">Dissociators</td>
<td>BV02</td>
</tr>
<tr>
<td class="label">Allosteric</td>
<td>Not identified</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">α-Synuclein</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Kinase regulation</td>
</tr>
<tr>
<td class="label">Parkin</td>
<td>E3 ligase regulation</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Phospho-dependent</td>
</tr>
<tr>
<td class="label">BAD</td>
<td>Pro-apoptotic sequestration</td>
</tr>
<tr>
<td class="label">BAX</td>
<td>Mitochondrial apoptosis</td>
</tr>
<tr>
<td class="label">RAF1</td>
<td>MAPK s

...

YWHAQ Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">YWHAQ Protein</th>
</tr>
<tr>
<td class="label">Client</td>
<td>Binding Site</td>
</tr>
<tr>
<td class="label">BAD</td>
<td>Ser112, Ser136</td>
</tr>
<tr>
<td class="label">BAX</td>
<td>Ser184</td>
</tr>
<tr>
<td class="label">RAF1</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">TRADD</td>
<td>Various</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Peptide inhibitors</td>
<td>R18 derivatives</td>
</tr>
<tr>
<td class="label">Stabilizers</td>
<td>Fusicoccin</td>
</tr>
<tr>
<td class="label">Dissociators</td>
<td>BV02</td>
</tr>
<tr>
<td class="label">Allosteric</td>
<td>Not identified</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">α-Synuclein</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Kinase regulation</td>
</tr>
<tr>
<td class="label">Parkin</td>
<td>E3 ligase regulation</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Phospho-dependent</td>
</tr>
<tr>
<td class="label">BAD</td>
<td>Pro-apoptotic sequestration</td>
</tr>
<tr>
<td class="label">BAX</td>
<td>Mitochondrial apoptosis</td>
</tr>
<tr>
<td class="label">RAF1</td>
<td>MAPK signaling</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

YWHAQ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Theta), also known as 14-3-3 theta or 14-3-3τ, is a member of the highly conserved 14-3-3 family of adapter proteins that regulate over 2,000 client proteins through phosphorylation-dependent interactions[@aitken2006][@gardino2009]. The 14-3-3 family consists of seven isoforms (β, ε, γ, η, σ, θ, ζ) that play essential roles in signal transduction, [cell cycle regulation](/entities/cell-cycle), [apoptosis](/entities/apoptosis), [metabolism](/entities/metabolism), and [stress responses](/entities/oxidative-stress)[@morrison2009]. In the nervous system, 14-3-3 proteins have emerged as critical modulators of neurodegeneration, with particular relevance to [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis)[@wang2014][@xing2020].

Protein Structure

Primary Structure

YWHAQ is a 245-amino acid protein with a molecular weight of approximately 28 kDa. The protein lacks intrinsic enzymatic activity and functions purely as an adapter/scaffold[@aitken2006].

Three-Dimensional Architecture

The 14-3-3 proteins share a highly conserved structure[@gardino2009][@obsilova2021]:

Nine Helices (αA-αI): Form a boomerang-shaped amphipathic dimer
Phosphopeptide-binding Groove: Formed by the dimer interface, recognizing phosphorylated serine/threonine motifs
Client Protein Interaction Surface: Extended surface area for diverse client interactions

Dimerization

14-3-3 proteins function as obligatory dimers, with each monomer capable of binding independent client proteins[@gardino2009]:

Parallel dimer arrangement: Creates a phosphopeptide-binding groove
Allosteric regulation: Client binding can influence the opposite monomer
Isoform mixing: Can form heterodimers between different 14-3-3 isoforms

Molecular Mechanisms

Phosphorylation-Dependent Substrate Recognition

YWHAQ binds to client proteins containing phosphorylated serine/threonine residues within specific motifs[@aitken2006][@yaffe1997]:

Mode I: RSXpS/pT (Arg/Ser-X-pSer/pThr)
Mode II: RXXXpS/pTXP (Arg-any-any-any-pSer/pThr-any-Pro)
Mode III: pS/pT within specific contexts

Key Signaling Pathways Regulated by YWHAQ

MAPK/ERK Signaling

Binds to and regulates BRAF, RAF1, and MEK1/2
Modulates MAPK cascade output
Influences neuronal differentiation and survival[@zhang2010]

PI3K/Akt Signaling

Interacts with Akt and PDK1
Regulates AKT membrane localization
Influences cell survival decisions

Cell Cycle Control

Binds to CDK-cyclin complexes
Regulates G1/S and G2/M transitions
Controls entry into mitosis[@luk2010]

Apoptosis Regulation

Sequesters pro-apoptotic proteins BAD and BAX
Prevents mitochondrial permeabilization
Promotes cell survival under stress[@masters2010]

Client Protein Examples

Role in Neurodegeneration

Parkinson's Disease

YWHAQ has emerged as a particularly important player in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis[@wang2014][@dumitriu2016][@wong2015]:

Lewy Body Pathology

14-3-3 proteins are major components of [Lewy bodies](/entities/lewy-bodies)
YWHAQ co-aggregates with α-synuclein in PD brains
May represent a protective sequestration mechanism

LRRK2 Interaction

YWHAQ binds to pathogenic LRRK2 mutations (G2019S, R1441C/G/H)
Modulates LRRK2 kinase activity and cellular toxicity
Potential therapeutic target for LRRK2-linked PD

Dopaminergic Neuron Survival

Protects against MPTP-induced parkinsonism
Binds and sequesters pro-apoptotic proteins
Expression reduced in vulnerable substantia nigra [neurons](/entities/neurons)

Parkin Regulation

14-3-3θ binds to parkin and regulates its E3 ligase activity
Disrupted interaction may contribute to mitophagy defects
Links mitochondrial dysfunction to protein aggregation

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease), 14-3-3 proteins show complex involvement[@xing2020][@qureshi2013]:

[Tau](/proteins/tau) Pathology

14-3-3θ can bind to hyperphosphorylated tau
May facilitate tau aggregation or clearance
Detected in neurofibrillary tangles

Amyloid-β Signaling

Modulates [amyloid-beta](/proteins/amyloid-beta)-induced toxicity
Regulates [APP](/entities/app-protein) processing indirectly
Altered expression in AD brain regions

Synaptic Dysfunction

14-3-3θ regulates synaptic plasticity proteins
Influences [NMDA receptor](/entities/nmda-receptor) trafficking
May contribute to early synaptic deficits

Amyotrophic Lateral Sclerosis

14-3-3 proteins are implicated in [ALS](/diseases/amyotrophic-lateral-sclerosis) pathogenesis[@brotherton2019]:

Binding to mutant SOD1 aggregates
Interaction with [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology
Motor neuron vulnerability factors

Huntington's Disease

In [Huntington's disease](/diseases/huntingtons)[@zhang2017]:

Mutant [huntingtin](/proteins/huntingtin) disrupts 14-3-3 function
Alters subcellular localization
Contributes to transcriptional dysregulation

Prion Disease

14-3-3θ is a well-established biomarker in [prion diseases](/diseases/creutzfeldt-jakob)[@collins2015]:

Elevated in cerebrospinal fluid
Reflects neuronal damage
Used in clinical diagnosis

Genetic Associations

Polymorphisms

rs1043981: Missense variant with debated association to PD
rs2297522: 3'UTR variant influencing expression
Haplotype structures show population-specific effects[@genetics2019]

Expression Studies

Increased YWHAQ in PD substantia nigra
Decreased expression in AD [hippocampus](/brain-regions/hippocampus)
Cell type-specific alterations in neurodegeneration

Animal Models

Knockout Studies

Ywhaq knockout mice: Viable with subtle neurological phenotypes
Synaptic plasticity deficits: Impaired [LTP](/mechanisms/long-term-potentiation) in hippocampal slices
Increased neuronal apoptosis: Enhanced vulnerability to stress[@che2011]

Transgenic Models

14-3-3θ overexpression: Protects against α-synuclein toxicity
Conditional expression: Reverses some PD-like phenotypes
Isoform-specific effects: Different isoforms have distinct functions[@zhou2018]

Therapeutic Targeting

Small Molecule Modulators

Therapeutic Strategies

Client-specific targeting: Focus on specific disease-relevant interactions

Peptide-based approaches: Cell-penetrating peptides to modulate interactions

Gene therapy: Modulate expression in target tissues

Combination approaches: Target multiple 14-3-3 interactions simultaneously

Challenges

Broad client network creates off-target concerns
Isoform-selectivity difficult to achieve
[Blood-brain barrier](/entities/blood-brain-barrier) penetration required
Therapeutic window must be carefully defined[@cao2021]

Biomarker Potential

Diagnostic Applications

Cerebrospinal fluid 14-3-3: Established marker for prion disease
Blood-based detection: Under development for PD and AD
Pet imaging agents: Not yet available

Disease Progression

Correlates with clinical measures in PD
May predict cognitive decline in AD
Potential for monitoring treatment response

Client-specific Signatures

Different client patterns may indicate specific pathways activated
Phospho-14-3-3 signatures under investigation
Personalized medicine applications possible

Interactions

Protein-Protein Interactions

Post-Translational Modifications

Phosphorylation: Multiple sites regulate client binding
Acetylation: Influences dimer stability
Oxidative modification: Affects function under stress
Ubiquitination: Targets for degradation[@jetton2019]

Expression and Localization

Brain Distribution

Neuronal expression: High in pyramidal neurons
Glial expression: Present in [astrocytes](/entities/astrocytes) and [microglia](/cell-types/microglia-neuroinflammation)
Regional variation: Highest in hippocampus and [cortex](/brain-regions/cortex)

Subcellular Localization

Cytoplasmic: Major pool, involved in signaling
Nuclear: Regulates transcription factors
Mitochondrial: Imported in response to stress
Synaptic: Localized to presynaptic terminals

Future Directions

Development of selective 14-3-3θ modulators
Understanding isoform-specific functions
Clinical biomarker validation
Gene therapy approaches
Combination with disease-modifying therapies

[YWHAQ Gene](/genes/ywhaq)
[14-3-3 Protein Family](/entities/14-3-3-proteins)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[LRRK2 Gene](/genes/lrrk2)
[Parkin Gene](/genes/parkin)
[Tau Protein](/proteins/tau)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Lewy Body Pathology](/entities/lewy-bodies)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Aitken, 14-3-3 proteins: a historic overview (2006) (2006)](https://doi.org/10.1016/j.semcancer.2006.04.005)

[Gardino et al., Structural determinants of 14-3-3 client interactions (2009) (2009)](https://doi.org/10.1016/j.tibs.2009.06.005)

[Unknown, Morrison, The 14-3-3 proteins (2009) (2009)](https://doi.org/10.1016/j.tcb.2009.05.004)

[Wang et al., 14-3-3 proteins in Parkinson's disease (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24513008/)

[Xing et al., 14-3-3 proteins in Alzheimer's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32029901/)

[Obsilova et al., 14-3-3 proteins: a family of molecular hubs (2021) (2021)](https://doi.org/10.1016/j.tibs.2021.01.009)

[Yaffe et al., Phosphopeptide recognition by 14-3-3 proteins (1997) (1997)](https://doi.org/10.1016/S0092-8674(00)

[Zhang et al., 14-3-3 and MAPK signaling (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20932476/)

[Luk et al., 14-3-3 in cell cycle control (2010) (2010)](https://doi.org/10.1016/j.semcdb.2010.08.002)

[Masters et al., 14-3-3-mediated apoptosis regulation (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20538036/)

[Dumitriu et al., 14-3-3θ and LRRK2 in PD (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27215564/)

[Wong et al., 14-3-3 proteins in dopaminergic neurons (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25903908/)

[Qureshi et al., 14-3-3 in tauopathies (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24322488/)

[Brotherton et al., 14-3-3 and ALS pathogenesis (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31113287/)

[Zhang et al., 14-3-3 in Huntington's disease (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28065471/)

[Collins et al., Cerebrospinal fluid 14-3-3 in prion disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26206856/)

[Unknown, Genetics of Parkinson's Disease Consortium, 14-3-3 genetic associations (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30665862/)

[Che et al., Ywhaq knockout mouse phenotype (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21360190/)

[Zhou et al., 14-3-3 transgenic models of PD (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29526584/)

[Cao et al., Targeting 14-3-3 proteins for therapy (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34002945/)

[Jetton et al., 14-3-3 post-translational modifications (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31151918/)

📖 View canonical wiki page →

Related Entities

YWHAQPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-ywhaq-protein
kg_node_id	YWHAQPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-dafd7822862c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-ywhaq-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

10

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

YWHAQ Protein

YWHAQ Protein

Overview

YWHAQ Protein

Overview

Protein Structure

Primary Structure

Three-Dimensional Architecture

Dimerization

Molecular Mechanisms

Phosphorylation-Dependent Substrate Recognition

Key Signaling Pathways Regulated by YWHAQ

MAPK/ERK Signaling

PI3K/Akt Signaling

Cell Cycle Control

Apoptosis Regulation

Client Protein Examples

Role in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Prion Disease

Genetic Associations

Polymorphisms

Expression Studies

Animal Models

Knockout Studies

Transgenic Models

Therapeutic Targeting

Small Molecule Modulators

Therapeutic Strategies

Challenges

Biomarker Potential

Diagnostic Applications

Disease Progression

Client-specific Signatures

Interactions

Protein-Protein Interactions

Post-Translational Modifications

Expression and Localization

Brain Distribution

Subcellular Localization

Future Directions

Related Pages

See Also

External Links

References

💬 Discussion